Cover Image
Market Research Report

Merck KGaA Company Analysis

Published by Datamonitor Healthcare Product code 603918
Published Content info 50 Pages
Delivery time: 1-2 business days
Price
Back to Top
Merck KGaA Company Analysis
Published: August 24, 2018 Content info: 50 Pages
Description

PharmaVitae explores Merck KGaA's prescription pharmaceutical performance and outlook over 2017-27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Snapshot

  • Overview - Merck KGaA's sparse late-stage pipeline and exposure to generics mean an increased reliance on its PD-L1 therapy Bavencio.
  • Key themes - [1] Merck KGaA's revenue continues to be negatively impacted by branded and generic competition to its portfolio of longer-listed products [2] Merck KGaA is attempting to combat these sales declines through its foray into the lucrative immuno-oncology market, and the launch of Mavenclad in multiple sclerosis [3] The company's CNS portfolio will decline at a CAGR of -1.8% out to 2027 as it loses prominence in multiple sclerosis [4] Oncology will be a key growth driver for Merck KGaA, growing at a 3.0% CAGR out to 2027 [5] Merck KGaA's outlook remains highly dependent on the successful further development of Bavencio.
  • Q1 2018 - Merck KGaA reports weak sales exacerbated by currency headwinds.
  • Out to 2022 - The expiries of longer-listed products will be partially offset by the 2017 launch of Bavencio, and growth in emerging markets.
  • Out to 2027 - The company will add $194m out to 2027, owing to growth in its oncology and metabolic portfolios, and the launch of Mavenclad.
  • Pipeline - Merck KGaA currently has no new molecular entity drugs in clinical development, and is heavily reliant on label expansions for Bavencio and Mavenclad.
  • Lifecycle - Merck KGaA's launch portfolio, focused on Bavencio and Mavenclad, will be sufficient in offsetting its principal pharma declines.
  • Major events - Bavencio will continue its expansion across solid tumor types as Mavenclad seeks approval in the US for multiple sclerosis.

Model updates

  • Reduced RoW sales owing to currency headwinds.
  • Merck KGaA acquires the rights to abituzumab from SFJ.
  • Divestiture of consumer healthcare business.

Analysis structure

  • Explore and visualize revenue dynamics in Merck KGaA's portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.

Quarterly review

  • What were the major highlights from Merck KGaA's latest earnings call and quarterly performance?

Strategy analysis

  • How is Merck KGaA strategically poised out to 2027?
  • What are Merck KGaA's key strengths, weaknesses, opportunities, and threats?
  • What are Merck KGaA's key catalysts during the current year?

Portfolio analysis

  • Why will specific therapy areas experience the largest growth and decline?
  • What are the detailed competitive dynamics at play in Merck KGaA's important therapeutic markets?
  • How is Merck KGaA adapting strategically to internal and external headwinds in preceding quarters?

Facts and figures

  • What is Merck KGaA's forecasted sales performance out to 2027?
  • What is the revenue trajectory of Merck KGaA's current top 10 products out to 2027?
  • Which therapy areas will experience the largest growth and decline?
  • What are the portfolio weightings of Merck KGaA based on the lifecycle of its products?
Table of Contents
Product Code: DMKC0200044

TABLE OF CONTENTS

OVERVIEW

  • Snapshot
  • Model updates
  • Analysis structure

Q2 2018 REVIEW

  • Merck KGaA's healthcare revenue reaches a new low
  • Bibliography

Q1 2018 REVIEW

  • Merck KGaA reports weak sales exacerbated by currency headwinds
  • A negative exchange rate sharply impacts healthcare revenue Q1 2018 highlights
  • Q1 2018 highlights
  • Mid-stage clinical potential
  • Bibliography

Q4 2017 REVIEW

  • Merck KGaA healthcare revenues grow by 2% in 2017 amid strong competitive pressures
  • Core products show organic decline amid strong competitive challenges
  • Bavencio development setbacks
  • Mavenclad launch strengthens Merck KGaA's presence in MS
  • Bibliography

Q3 2017 REVIEW

  • Merck KGaA reports falling revenues due to pressures to Rebif and Erbitux
  • Bavencio approvals in Merkel cell carcinoma
  • Mavenclad approval in Europe
  • Divestment of businesses
  • Q3 2017 events
  • Bibliography

STRATEGY ANALYSIS

  • Healthcare focus
  • Full-year 2017 results
  • Key priorities outlined for 2018
  • Net debt to EBITDA ratio
  • Divestment of businesses
  • Merck KGaA's SWOT analysis
  • Merck KGaA's key events and catalysts
  • Bibliography

PORTFOLIO ANALYSIS

Q2 2018

FACTS AND FIGURES

  • Merck KGaA's prescription pharma sales outlook
  • Merck KGaA's regional pharma sales outlook
  • Merck KGaA's therapy area dynamics
  • Merck KGaA's growth drivers and resistors
  • Merck KGaA's portfolio lifecycle analysis
  • Merck KGaA's pipeline analysis
  • Merck KGaA's M&A strategy and history
  • Bibliography

LIST OF FIGURES

  • Figure 1: Merck KGaA's prescription pharmaceutical sales ($m) and growth rate (%), 2014-27
  • Figure 2: Merck KGaA's therapy area dynamics, 2017-27
  • Figure 3: Merck KGaA's launch/core/expiry portfolio configuration, 2017-27
  • Figure 4: Merck KGaA's pipeline overview

LIST OF TABLES

  • Table 1: Merck KGaA's established core product quarterly sales (€m)
  • Table 2: Merck KGaA's sales by therapy area ($m), 2017-27
  • Table 3: Merck KGaA's prescription pharmaceutical sales by region ($m), 2017-27
  • Table 4: Merck KGaA's sales by therapy area ($m), 2017-27
  • Table 5: Merck KGaA's CNS portfolio sales, by product ($m), 2017-27
  • Table 6: Merck KGaA's oncology portfolio sales, by product ($m), 2017-27
  • Table 7: Merck KGaA's key products, 2017-27
  • Table 8: Merck KGaA's sales by launch, core, and expiry portfolio ($m), 2017-27
  • Table 9: Merck KGaA's launch portfolio sales, by product ($m), 2017-27
  • Table 10: Merck KGaA's key merger and acquisition deals, 2003-18
Back to Top